Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

Angiotensin II, the principal effector peptide of the renin-angiotensin-aldosterone system (RAAS), has potent vasoconstrictive and other effects that can lead to cardiac and renal complications.

A nurse performs vital signs monitoring (VSM). A team of researchers analyzed the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on patients with COVID-19 with ...

DALLAS, June 3, 2022 — A multi-center study of more than 3,000 people with high blood pressure and brain aneurysms found that the use of RAAS inhibitors, a class of blood pressure lowering medications ...

A multi-center study of more than 3,000 people with high blood pressure and brain aneurysms found that the use of RAAS inhibitors, a class of blood pressure lowering medications, reduced the risk of ...

In patients with COVID-19 treated for hypertension, the use of renin-angiotensin-aldosterone system (RAAS) inhibitors was associated with a lower risk of COVID-19 hospitalisation and all-cause ...

A new study has found that RAAS inhibitors, a class of blood pressure-lowering medicine, may be better at reducing the risk of brain aneurysm rupture. People with a brain aneurysm -- a weakened area ...